Left ventricular assist devices (LVAD) provide cardiac support for patients with end-stage
heart disease as either bridge or destination therapy, and have significantly improved the …

Bleeding events remain a significant and frequent complication of continuous-flow left
ventricular assist devices (VADs). von Willebrand factor (VWF) is critical to hemostasis by …

Essentials• Relationship of acquired von Willebrand disease (VWD) and platelet dysfunction
is explored.• Patients with ventricular assist devices and on extracorporeal membrane …

Objectives Bleeding is an important source of morbidity in patients with a left ventricular
assist device. Evidence suggests a major role for von Willebrand factor. However, limited …

Rationale: The objective of this autopsy study was to determine whether gastrointestinal
angiodysplasia develops during continuous-flow left ventricular assist device (LVAD) …

OBJECTIVES: Impaired binding of Von Willebrand factor (VWF) to platelets and to collagen
due to acquired Von Willebrand syndrome (AVWS) is associated with support from a …

Patients supported by left ventricular assist devices (LVADs) often present with the loss of
large von Willebrand factor (VWF) multimers. This VWF deficiency is believed to contribute to …

Background: Acquired von Willebrand syndrome (AvWS) in the setting of congenital heart
disease is an under-recognized cause of bleeding in the pediatric cardiac critical care unit …

Left ventricular assist devices (LVADs) provide short-or long-term circulatory support to
improve survival and reduce morbidity in selected patients with advanced heart failure …

Von Willebrand factor (VWF) is a large multimeric glycoprotein involved in hemostasis. It is
essential for platelet adhesion to the subendothelium of the damaged endothelial layer at …